Portola Pharmaceuticals Provides Update on European Marketing Authorization Application for Betrixaban
12 déc. 2017 08h30 HE
|
Portola Pharmaceuticals, Inc.
South San Francisco, Calif., Dec. 12, 2017 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc.® (Nasdaq:PTLA) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the...
Portola Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
05 déc. 2017 16h14 HE
|
Portola Pharmaceuticals, Inc.
SOUTH SAN FRANCISCO, Calif., Dec. 05, 2017 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc.® (NASDAQ:PTLA) announced today that on November 27, 2017, the Compensation Committee of the Board of...
Portola Pharmaceuticals to Present New Data on Betrixaban, Andexanet Alfa and Cerdulatinib at the 59th American Society of Hematology (ASH) Annual Meeting
30 nov. 2017 08h00 HE
|
Portola Pharmaceuticals, Inc.
SOUTH SAN FRANCISCO, Calif., Nov. 30, 2017 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc.® (Nasdaq:PTLA) today announced that new data on the Company’s first FDA-approved anticoagulant,...
Portola Pharmaceuticals Provides Update on Bevyxxa® (betrixaban) Commercial Launch
21 nov. 2017 18h22 HE
|
Portola Pharmaceuticals, Inc.
SOUTH SAN FRANCISCO, Calif., Nov. 21, 2017 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc.® (NASDAQ:PTLA) today announced that the U.S. Food and Drug Administration (FDA) has extended the review...
Portola Pharmaceuticals Announces New APEX Study Sub-Analyses Data on Betrixaban to be Presented at the America Heart Association (AHA) Scientific Sessions 2017
07 nov. 2017 08h00 HE
|
Portola Pharmaceuticals, Inc.
SOUTH SAN FRANCISCO, Calif., Nov. 07, 2017 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals Inc.® (Nasdaq:PTLA) today announced that results of new sub-analyses of the APEX Study of betrixaban will be...
Portola Pharmaceuticals Reports Third Quarter 2017 Financial Results and Provides Corporate Update
06 nov. 2017 16h01 HE
|
Portola Pharmaceuticals, Inc.
SOUTH SAN FRANCISCO, Calif., Nov. 06, 2017 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals Inc.® (Nasdaq:PTLA) will today report financial results and provide a corporate update for the quarter ended...
Portola Pharmaceuticals Appoints Industry Veteran John H. Lawrence, M.D., as Senior Vice President of Product Development and Chief Medical Officer
06 nov. 2017 08h00 HE
|
Portola Pharmaceuticals, Inc.
SOUTH SAN FRANCISCO, Calif., Nov. 06, 2017 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals (Nasdaq:PTLA) today announced the appointment of John H. (Jack) Lawrence, M.D., as senior vice president and...
Portola Pharmaceuticals to Present at the Credit Suisse 26th Annual Healthcare Conference
03 nov. 2017 08h00 HE
|
Portola Pharmaceuticals, Inc.
SOUTH SAN FRANCISCO, Calif., Nov. 03, 2017 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals (Nasdaq:PTLA) today announced that Bill Lis, chief executive officer, will present at the Credit Suisse 26th...
Portola Pharmaceuticals to Announce Third Quarter 2017 Financial Results and Host Conference Call on Monday, November 6
30 oct. 2017 08h00 HE
|
Portola Pharmaceuticals, Inc.
SOUTH SAN FRANCISCO, Calif., Oct. 30, 2017 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc.® (Nasdaq:PTLA) today announced that it will host a webcast and conference call to discuss the company’s...
Portola Pharmaceuticals Supports 2017 World Thrombosis Day Campaign to Raise Awareness about the Persistent Risk of Blood Clots
11 oct. 2017 16h05 HE
|
Portola Pharmaceuticals, Inc.
SOUTH SAN FRANCISCO, Calif., Oct. 11, 2017 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals Inc.® (Nasdaq:PTLA) announced today that it will be serving as a global partner for World Thrombosis Day to...